0.044
0.000
(0.00%)
Jun 18 - Close
ASX
data delayed by 20 mins -
Disclaimer
Currency in AUD
| Range | - |
| 52 week | 0.04 - 0.06 |
| Open | - |
| Vol / Avg. | 0.00/171,007.00 |
| Mkt cap | 15.71M |
| P/E | - |
| Div/yield | - |
| EPS | -0.01 |
| Shares | 357.00M |
| Beta | - |
| Inst. own | - |
Events
Apr 29, 2013
Living Cell Technologies Ltd KPI Quarterly Report - March 2013
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -7.80% | 147.93% |
| Operating margin | -7.80% | 147.93% |
| EBITD margin | - | -78.86% |
| Return on average assets | -3.34% | 49.37% |
| Return on average equity | -3.59% | 53.77% |
| Carbon Disclosure Rating | - | - |
Address
Level 5, NAB House Hunters Corner, Manukau PO Box 23566
Sydney, AUC 2155
New Zealand
+64-9-2762690 (Phone)
+64-9-2762691 (Fax)
Sydney, AUC 2155
New Zealand
+64-9-2762690 (Phone)
+64-9-2762691 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Living Cell Technologies Limited is an Australian- based live cell therapy Company. The principal activities of the Company were developing treatments for implanting healthy living cells to replace or repair diseased or damaged organs, for a range of life-threatening diseases and developing NTCELL, a suite of products for neurological disorders, which are at various stages of pre-clinical development and discovery. The Company focuses on developing treatments for implanting healthy living cells to replace or repair diseased or damaged organs, for a range of life-threatening diseases. The Company operates in one main division, which is the research, development, manufacturing and clinical division is located in Auckland, New Zealand. The Company�s subsidiaries include Living Cell Products Pty Ltd, LCT Australia Pty Ltd, Pancell New Zealand Ltd, LCT BioPharma Ltd, Living Cell Technologies S.A., LCT Biomedical Ltd and Fac8Cell Pty Ltd.
Officers and directors
| Roy Austin | Independent Chairman of the Board | |
| Andrea Grant | Chief Executive Officer, Managing Director | |
| John Cowan | Head of Finance and Administration | |
| Robert Bartlett Elliott M.D. | Chief Science and Medical Officer | |
| Paul Tan | Chief Science and Medical Officer (CSMO) | |
| Nick Geddes | Company Secretary | |
| Laurie Hunter | Independent Director | |
| Bernard Tuch Ph.D. | Independent Director | |
| Robert M Willcocks | Independent Director |